Effects of Zolmitriptan (ZomigTM) on Central Serotonergic Neurotransmission as Assessed by Active Oddball Auditory Event-Related Potentials in Volunteers without Migraine

In this randomized, double-blind, three-period crossover trial, 24 healthy volunteers without migraine received zolmitriptan 5 mg, dexfenfluramine 15 mg or placebo orally. At 2, 6, and 24 h postdose, auditory stimuli of 1000 Hz (nontarget tone) and 2000 Hz (target tone) were randomly and binaurally presented in an active oddball paradigm (4:1 ratio). Cortical auditory evoked responses were recorded for 500 msec poststimulus. Plasma concentrations of zolmitriptan and a 17-lead quantitative EEG were assessed at the same timepoints. Relative to placebo, zolmitriptan reduced the maximum absolute amplitude, amplitude difference (from nontarget tone noise) and area under the curve of the cortical auditory target tone event-related potential (P300 ERP). The most dramatic effect of zolmitriptan was to diminish the point estimate of noise during the 200-400 msec poststimulus epoch. The effect of zolmitriptan appeared concentration dependent. The latency of the P300 ERP was unaffected by zolmitriptan and there was no clinically significant effect on the EEG. Modification by zolmitriptan of the cortical electrical activity evoked by auditory stimuli confirms a central action of this drug in humans, which appears to affect cortical information processing without global alteration of the quantitative EEG.

[1]  Georg Juckel,et al.  Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: A new hypothesis , 1993, Biological Psychiatry.

[2]  Y. Hochberg.  A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[3]  H. Jasper.  Report of the committee on methods of clinical examination in electroencephalography , 1958 .

[4]  Graham R. Martin.  Pre-clinical pharmacology of zolmitriptan (Zomig™; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine , 1997, Cephalalgia : an international journal of headache.

[5]  V. Gallai†,et al.  The Event‐Related Potential P300 During Headache‐Free Period and Spontaneous Attack in Adult Headache Sufferers , 1995, Headache.

[6]  B. Jacobs,et al.  Structure and function of the brain serotonin system. , 1992, Physiological reviews.

[7]  W. Pritchard.  Psychophysiology of P300. , 1981, Psychological bulletin.

[8]  P. Goadsby,et al.  Direct Evidence for Central Sites of Action of Zolmitriptan (311C90) , 1997, Cephalalgia : an international journal of headache.

[9]  R. Veselis,et al.  The P300 event-related potential during propofol sedation: a possible marker for amnesia? , 1995, British journal of anaesthesia.

[10]  N. Ramadan,et al.  Optimizing the dose of zolmitriptan (Zomig,* 311C90) for the acute treatment of migraine , 1997, Neurology.

[11]  J. Schoenen,et al.  Intensity Dependence of the Cortical Auditory Evoked Potentials as A Surrogate Marker of Central Nervous System Serotonin Transmission in Man: Demonstration of A Central Effect for the 5Ht1B/1D Agonist Zolmitriptan (311C90, Zomig®). , 1997, Cephalalgia : an international journal of headache.

[12]  M. Timsit-Berthier,et al.  Intensity dependence of auditory evoked potentials is pronounced in migraine , 1996, Neurology.

[13]  W. Wang,et al.  Interictal potentiation of passive "oddball" auditory event-related potentials in migraine. , 1998, Cephalalgia : an international journal of headache.

[14]  M. Kutas,et al.  Electrophysiology of cognitive processing. , 1983, Annual review of psychology.

[15]  J. Kemp,et al.  The Metabolism of Zolmitriptan , 1998, Clinical drug investigation.

[16]  P. Goadsby,et al.  Peripheral and Central Trigeminovascular Activation in Cat is Blocked by the Serotonin (5HT)‐I D Receptor Agonist 311C90 , 1994 .

[17]  H. Jasper,et al.  The ten-twenty electrode system of the International Federation. The International Federation of Clinical Neurophysiology. , 1999, Electroencephalography and clinical neurophysiology. Supplement.

[18]  J. Schoenen,et al.  Zolmitriptan (Zomig™, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: An overview of efficacy , 1997, Cephalalgia : an international journal of headache.

[19]  R. Tanner,et al.  Preclinical studies on the anti-migraine drug, sumatriptan. , 1991, European neurology.

[20]  J. Kemp,et al.  Effects of the Antimigraine Compound Zolmitriptan (‘Zomig’) on Psychomotor Performance Alone and in Combination with Diazepam in Healthy Volunteers , 1998, Cephalalgia : an international journal of headache.

[21]  M. Timsit-Berthier,et al.  Cognitive functions in migraine without aura between attacks: a psychophysiological approach using the “oddball” paradigm , 1995, Neurophysiologie Clinique/Clinical Neurophysiology.

[22]  R. Hen,et al.  Regulation of Serotonin Release in the Frontal Cortex and Ventral Hippocampus of Homozygous Mice Lacking 5‐HT1B Receptors: In Vivo Microdialysis Studies , 1997, Journal of neurochemistry.

[23]  J. Schoenen.  Measuring central action of acute antimigraine drugs in humans , 1997, Cephalalgia : an international journal of headache.

[24]  J Weissenburger,et al.  The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. , 1995, British journal of clinical pharmacology.

[25]  M. Drake,et al.  Long‐latency Auditory Event Related Potentials in Migraine , 1989, Headache.

[26]  J. Rhodes,et al.  Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. , 2001, British journal of clinical pharmacology.

[27]  Edmeads Jg,et al.  Tolerability Profile of Zolmitriptan (Zomig™; 311C90), a Novel Dual Central and Peripherally Acting 5HT1B/1D Agonist: International Clinical Experience Based on > 3000 Subjects Treated with Zolmitriptan , 1997 .

[28]  Emanuel Donchin,et al.  The P300 component of the event-related brain potential as an index of information processing , 1982, Biological Psychology.